Pluripotent Stem Cells
Pluristyx is proud to offer off-the-shelf NIH-approved Human Pluripotent Stem Cells for immediate evaluation. These iPSC lines are generated from our proprietary cellular reprogramming technology. Pluristyx's catalogue of stem cells are fully characterized to ensure pluripotency and genetic stability of the cells with a clinical application in mind.
iPSCs are generated from regulatory-compliant donors and can be evaluated to assist in the selection of lines appropriate for your research. Our portfolio of cell lines includes both research and GMP clinical grade cell lines. Our products can be used to assist with PSC scale up for clinical product generation.
We offer unmodified lines, gene edited lines and disease-affected versions available for purchase or licensing. Pluristyx is also able to offer custom iPSC lines from clinically compliant material of your choice to match desired donor characteristics.
PluriBank™ RUO FailSafe® lines that features enhanced immune evasion through reduced T cell recognition and a selective ablation mechanism to remove dividing cells while preserving post-mitotic cells. This innovative line integrates mRNA-reprogrammed iPSCs with CRISPR-based knockouts of B2M and CIITA genes, plus the FailSafe safety switch.
Achieving reproducible iPSC growth has long been a challenge, especially with the availability of various reagents and methods creating endless combinations. To address this, Pluristyx has developed PluriKit, an integrated solution specifically designed to support the reproducible culture of PluriBank lines.
Pluristyx can employ our cellular reprogramming technology to generate custom iPSC lines available in Research and Clinical grade. Custom iPS cell lines can be further modified to include our licensed gene edited technologies, FailSafe® or iACT Stealth Cell™, as well as your custom genetic edits to generate the ideal starting material for your downstream product development and clinical manufacturing.
Pluristyx has expertise in iPSC reprogramming and the development of cellular differentiation protocols to generate a wide range of derivative cell types from iPSCs. These cell types include mesenchymal and hematopoietic stem cells.